Neulasta (pegfilgrastim) - Amgen, Kyowa Hakko Kirin, Roche
Eylea (aflibercept intravitreal) - Bayer, Regeneron
Udenyca (pegfilgrastim biosimilar) - Coherus
Zaltrap (ziv-aflibercept IV) - Sanofi, Regeneron
CHS-3351 (ranibizumab biosimilar) - Coherus
Humira (adalimumab) - Eisai, AbbVie
FYB201 (ranibizumab biosimilar) - Amneal, Formycon
CHS-1420 (adalimumab biosimilar) - Coherus
http://www.globenewswire.com/news-release/2019/11/06/1942551/0/en/Coherus-BioSciences-Reports-Corporate-Highlights-and-Third-Quarter-2019-Financial-Results.html
 
Nov 6, 2019
 
Prev Next